The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Reductions in JAK2V617F allele burden with ruxolitinib treatment in COMFORT-II, a phase III study comparing the safety and efficacy of ruxolitinib to best available therapy (BAT).
Alessandro M. Vannucchi
Consultant or Advisory Role - Italfarmaco; Italfarmaco; Novartis; Novartis
Honoraria - Italfarmaco; Italfarmaco; Novartis; Novartis
Jean-Jacques Kiladjian
Research Funding - Celgene; Novartis; Shire
Heinz Gisslinger
No relevant relationships to disclose
Francesco Passamonti
Consultant or Advisory Role - Celgene; Novartis; Sanofi
Haifa Kathrin Al-Ali
Honoraria - Novartis
Research Funding - Novartis
L. Andres Sirulnik
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Viktoriya Stalbovskaya
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Matthew Squires
Employment or Leadership Position - Novartis
Deborah S. Hunter
Employment or Leadership Position - Incyte
Stock Ownership - Incyte
Timothy Burn
Employment or Leadership Position - Incyte
Stock Ownership - Incyte
Laurent Knoops
Consultant or Advisory Role - Novartis
Expert Testimony - Novartis
Francisco Cervantes
Consultant or Advisory Role - Novartis
Tiziano Barbui
No relevant relationships to disclose
Giovanni Barosi
No relevant relationships to disclose
Claire N Harrison
Consultant or Advisory Role - Celgene; Celgene; Novartis; Novartis; S Bio; Sanofi ; YM BioSciences; YM BioSciences
Honoraria - Celgene; Celgene; Novartis; Novartis; S Bio; Sanofi ; Sanofi ; SBio; YM BioSciences; YM BioSciences
Research Funding - Novartis; Novartis
Expert Testimony - SBio; SBio